1 Originally FDA-approved for type 2 diabetes, GLP-1 RAs also lead to sustained weight loss and have revolutionized diabetes and obesity management
Not all side effects are mild
Estimated medication-level charts can provide a model-based view, but they cannot tell an individual what is happening clinically or when a dose should change
Additionally, GLP-1RAs exhibit pleiotropic effects on metabolic and cardiovascular pathways, which could influence arrhythmia risk through mechanisms such as glucose homeostasis, blood pressure regulation, and autonomic modulation
These findings do not mean the drugs are damaging the thyroid in a predictable way
Instead, the market is driven by specialized peptide synthesis laboratories catering exclusively to in vitro and animal research